Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

被引:102
作者
Gounden, Verena [1 ,2 ]
van Niekerk, Chantal [1 ,2 ]
Snyman, Tracy [1 ,2 ]
George, Jaya A. [1 ,2 ]
机构
[1] Univ Witwatersrand, Dept Chem Pathol, Fac Hlth Sci, ZA-2001 Johannesburg, South Africa
[2] Charlotte Maxeke Acad Hosp, Natl Hlth Lab Serv, Johannesburg, South Africa
来源
AIDS RESEARCH AND THERAPY | 2010年 / 7卷
关键词
POPULATION PHARMACOKINETICS; TREATMENT FAILURE; METABOLISM; THERAPY; IDENTIFICATION; INDIVIDUALS; VARIABILITY; PREVALENCE; ALLELES; VARIANT;
D O I
10.1186/1742-6405-7-32
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The 516G > T polymorphism in exon 4 of the CYP2B6 gene has been associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations greater than the recommended therapeutic range have been associated with the increased likelihood of developing adverse CNS effects. The aims of this study were to a) determine the presence of the 516G > T and other CYP2B6 exon 4 polymorphisms in a South African group of HIV-infected individuals b) investigate the relationship between the EFV plasma concentrations, the CYP2B6 516G > T polymorphism and the occurrence of CNS related side effects in this group of patients and c) develop and validate a rapid method for determination of EFV in plasma. Method: Data from 80 patients is presented. Genetic polymorphisms in exon 4 of the CYP2B6 gene were identified using PCR amplification of this region followed by sequencing of the amplification products. EFV concentrations were analysed by UPLC-MS/MS. Assessment of the presence of CNS related side effects following EFV initiation were elicited with the use of a questionnaire together with physical examination. Results: Plasma EFV concentrations displayed high inter-individual variability amongst subjects with concentrations ranging from 94 mu g/l to 23227 mu g/l at 2 weeks post initiation of treatment. For the 516G > T polymorphism the following frequencies were observed 23% of patients were TT homozygous, 36% GG and 41% GT. The TT homozygous patients had significantly higher EFV concentrations vs. those with the wild (GG) genotype (p < 0.05). Patients who experienced no side effects had significantly lower EFV plasma concentrations vs. the group of patients which experienced the most severe side effects (p < 0.05). Conclusion: The significant association between the 516G > T polymorphism and plasma EFV concentrations has been demonstrated in this study. A rapid and sensitive method for the measurement of plasma EFV concentration was developed and validated.
引用
收藏
页数:9
相关论文
共 28 条
[1]  
American National Institute of Health, 2005, PRELIMINARY EVALUATI
[2]   Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy [J].
Boulle, Andrew ;
Van Cutsem, Gilles ;
Cohen, Karen ;
Hilderbrand, Katherine ;
Mathee, Shaheed ;
Abrahams, Musaed ;
Goemaere, Eric ;
Coetzee, David ;
Maartens, Gary .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05) :530-539
[3]   Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals [J].
Clifford, DB ;
Evans, S ;
Yang, YJ ;
Acosta, EP ;
Goodkin, K ;
Tashima, K ;
Simpson, D ;
Dorfman, D ;
Ribaudo, H ;
Gulick, RM .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (10) :714-721
[4]   Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection [J].
Csajka, C ;
Marzolini, C ;
Fattinger, K ;
Décosterd, LA ;
Fellay, J ;
Telenti, A ;
Biollaz, J ;
Buclin, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :20-30
[5]   In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function [J].
di Iulio, Julia ;
Fayet, Aurelie ;
Arab-Alameddine, Mona ;
Rotger, Margalida ;
Lubomirov, Rubin ;
Cavassini, Matthias ;
Furrer, Hansjakob ;
Guenthard, Huldrych F. ;
Colombo, Sara ;
Csajka, Chantal ;
Eap, Chin B. ;
Decosterd, Laurent A. ;
Telenti, Amalio .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (04) :300-309
[6]  
Flexner Charles W, 2003, Top HIV Med, V11, P40
[7]   Long-term neuropsychiatric disorders on efavirenz-based approaches:: Quality of life, psychologic issues, and adherence [J].
Fumaz, CR ;
Muñoz-Moreno, JA ;
Moltó, J ;
Negredo, EN ;
Ferrer, MJ ;
Sirera, G ;
Pérez-Alvarez, NR ;
Gómez, G ;
Burger, D ;
Clotet, B .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (05) :560-565
[8]   Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26 [J].
Gatanaga, Hiroyuki ;
Hayashida, Tsunefusa ;
Tsuchiya, Kiyoto ;
Yoshino, Munehiro ;
Kuwahara, Takeshi ;
Tsukada, Hiroki ;
Fujimoto, Katsuya ;
Sato, Isao ;
Ueda, Mikio ;
Horiba, Masahide ;
Hamaguchi, Motohiro ;
Yamamoto, Masahiro ;
Takata, Noboru ;
Kimura, Akiro ;
Koike, Takao ;
Gejyo, Fumitake ;
Matsushita, Shuzo ;
Shirasaka, Takuma ;
Kimura, Satoshi ;
Oka, Shinichi .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (09) :1230-1237
[9]  
Haas DW, 2004, AIDS, V18, P2391
[10]   Genetic variability of CYP2B6 in populations of African and Asian origin:: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz [J].
Klein, K ;
Lang, T ;
Saussele, T ;
Barbosa-Sicard, E ;
Schunck, WH ;
Eichelbaum, M ;
Schwab, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (12) :861-873